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Pneumonia remains the most common cause of hospitalization and the most important cause of death in young
children. In high human immunodeficiency virus (HIV)-burden settings, HIV-infected children carry a high burden
of lower respiratory tract infection from common respiratory viruses, bacteria and Mycobacterium tuberculosis.
In addition, Pneumocystis jirovecii and cytomegalovirus are important opportunistic pathogens. As the vertical
transmission risk of HIV decreases and access to antiretroviral therapy increases, the epidemiology of these
infections is changing, but HIV-infected infants and children still carry a disproportionate burden of these infections.
There is also increasing recognition of the impact of in utero exposure to HIV on the general health of exposed
but uninfected infants. The reasons for this increased risk are not limited to socioeconomic status or adverse
environmental conditions—there is emerging evidence that these HIV-exposed but uninfected infants may have
particular immune deficits that could increase their vulnerability to respiratory pathogens. We discuss the impact
of tuberculosis and other lower respiratory tract infections on the health of HIV-infected infants and children.
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To prevent vertical transmission of human immunodefi-
ciency virus (HIV) from mother to child and to improve
long-term outcomes for HIV-infected pregnant women,
the current standard of care is to initiate lifelong
suppressive antiretroviral therapy (ART) [1]. With this
strategy, transmission should be less than 1% in women
who either know their status, or are diagnosed early in
pregnancy and are retained in care on an effective
regimen [1, 2]. However, as vertical HIV transmission
risk decreases there is increasing recognition of adverse
health impacts suffered by HIV-exposed but uninfected
(HEU) infants, including vulnerability to developing
lower respiratory tract infections (LRTIs) and tubercu-
losis (TB) due to socioeconomic status and adverse
environmental conditions such as maternal ill health and
lack of breastfeeding [3]. In these infants there is also
increasing recognition of immune dysfunction including* Correspondence: hrabie@sun.ac.za
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and possibly humoral immunity [3].
Despite major reductions in vertical HIV transmission
among adequately treated mothers, large numbers of
HIV-infected children continue to be born, especially in
settings where HIV service delivery or maternal uptake
of available services is sub-optimal. In 2013, it was esti-
mated that globally there were 240,000 new pediatric
HIV infections [4]. In the absence of antiretroviral
therapy, perinatally infected infants and children have
high morbidity and mortality, with 50% dying by the
age of 2 years in low resource settings [5]. Despite the
high early mortality without ART, many perinatally in-
fected children have slowly progressive disease and some
may only be diagnosed in late childhood or adolescence
[6]. As established by clinical, epidemiological and
postmortem studies, LRTIs are the major cause of
morbidity and mortality in HIV-infected children. LRTIs
in HIV-infected children are from common childhood re-
spiratory pathogens (viral and bacterial), as well as
opportunistic pathogens, such as Pneumocystis jirovecii,
cytomegalovirus (CMV) and Mycobacterium tuberculosis
[7–11].le is distributed under the terms of the Creative Commons Attribution 4.0
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Epidemiology
The overlap in the epidemiology of TB and HIV is well
known, with its epicenter in sub-Saharan Africa. All of the
countries with HIV prevalence of more than 10% in
persons aged 15–49 years are in sub-Saharan Africa, and
more than 90% of all HIV-infected children live in this re-
gion [3, 12, 13]. In addition, all of the countries with a TB
incidence of more than 500 cases per 100,000 population
are in sub-Saharan Africa, although large case numbers
are also found in Asian countries with high population
numbers [12]. In settings with a high burden of both TB
and HIV, high rates of co-infection are reported and up to
56% of children treated for TB in sub-Saharan Africa are
considered to be HIV-infected [8]. Studies of HIV cohorts
confirm high rates of incident and prevalent TB. In Cape
Town, South Africa, TB program data suggested a TB
incidence of 1596 cases per 100,000 among HIV-infected
infants prior to the implementation of universal ART [14],
while clinical cohort data identified 53 cases per 100
patient-years in children not on ART [15]. A randomized-
controlled trial to assess the effect of universal isoniazid
preventive therapy (IPT) in HIV-infected children found a
TB disease rate of 121 per 1000 patient-years in children
who had early ART access [16].
Major differences in the number of children diagnosed
in TB endemic settings with comparable adult TB inci-
dence rates probably reflect varying ability to diagnose
TB in young children [8]. Irrespective of the setting, it
remains crucial to test all TB patients for HIV. This is
highlighted by cohort reports from multiple settings; in
the United Kingdom, 8 of 18 TB/HIV co-infected chil-
dren presented with TB, which prompted their HIV
diagnosis [17]. Studies of older children and adolescents
in Zimbabwe found a high yield of new HIV diagnosis in
adolescents presenting with TB [18]. Rates of TB are not
only increased in HIV-infected infants, but evidence sug-
gests that HEU infants are also at increased risk for TB.
Data from South Africa suggest this risk may be 4-fold
that of the general population [19], with rates of 41 cases
per 1000 child-years reported in HEU infants [16].
Reasons for the high rates of TB in HIV-infected in-
fants are multifactorial. HIV-infected and HEU infants
and children are highly exposed to adult TB source
cases. HIV-infected adults are 21–34 times more likely
to develop TB in high burden settings, with TB account-
ing for up to a quarter of HIV-associated mortality [20].
Woman of child-bearing age are disproportionately af-
fected [21], which implies a high risk of household TB
exposure in vulnerable young HIV-infected and HEU
children [22]. In a study of IPT in high TB burden
settings, 10% of HIV-exposed infants had contact with
potential source cases by the age of 14 weeks [23]. If TB
in HIV-infected pregnant women is missed, the infantsare not only at risk of TB, but have a 3-fold higher HIV
acquisition rate [24]. Where there are no strategies to
identify mothers with sputum smear-negative TB, there
may be significant delays in diagnosis and extended
exposure of young children to risk of infection [25, 26].
Alongside exposure and infection, young age is one of
the most important risk factors for developing severe
disease [27]. However, young age is poorly studied as a
risk factor in HIV-infected children in resource-limited
settings, but as many as 33% of infants starting ART at a
median age of 8 months are already receiving anti-TB
therapy [28]. Other risk factors are poor nutritional
status (stunting, wasting and reduced mid-upper arm
circumference), advanced immune suppression and
anemia [8]. School attendance is also associated with
disease in older children, reflecting poor ventilation in
schools in low-resource, high-burden settings [22].
Prevention
The most important tools we have to mitigate the HIV-
associated risk of developing TB infection and disease
are (i) access to ART for adults and children with HIV;
and (ii) use of IPT. In the Children with HIV Early
Antiretroviral Therapy (CHER) trial, conducted in Cape
Town and Johannesburg, South Africa, TB occurred in
8.3% of children receiving early ART (initiated before12
weeks of age) and in 20% of children receiving delayed
ART (commenced only after specific clinical and
immunologic criteria were met) [29]. When ART is
initiated in older children, reductions in presumed and
confirmed incident TB of 32–70% are documented [8].
Nevertheless, HIV-infected children have more TB than
their uninfected peers, including in low-burden settings
[8, 30]. A transient increase in risk can also be expected
in the first 3 months of therapy as part of immune re-
constitution inflammatory syndrome (IRIS) [31, 32].
Though there is a decline in the number of children
commencing ART only when they are severely immuno-
compromised, this situation is still common. In 2010 in
Asia, Africa and South America, 63% of HIV-infected
children in low-income countries, 66% in low–middle-in-
come and 58% in upper–middle-income countries were
already severely immunocompromised when commencing
ART, compared with 19% of HIV-infected children in the
United States [33]. Access to ART with broad penetration
into the community will impact the epidemiology of TB,
because there will be a decrease in adult cases of pulmon-
ary disease. This is already clear from the decline in adult
and pediatric TB cases in South Africa as the adult ART
uptake increased. In Soweto, South Africa, ART access in
TB in HIV-uninfected children declined from 18.7 to 11.0
per 100,000 [34].
In 2014, The Joint United Nations Programme on
HIV/AIDS (UNAIDS) defined its ambitious 90–90–90
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90% of HIV-infected persons must be diagnosed, 90% of
those diagnosed should be on sustained therapy, and
90% of those on therapy should have an undetectable
viral load [35]. If ART coverage expands to 80% of in-
fected persons and all infected persons are eligible for
therapy, the incidence of TB should decline by 28–37%.
However, even if these targets are achieved, finding and
treating TB cases remains important as it will prevent
mortality and reduce TB transmission [36].
IPT is a well known prevention strategy in HIV-
uninfected children and adults with known exposure to
TB. In HIV-infected children there are no studies asses-
sing post-exposure prevention; however, in a cohort of
494 children beginning ART when younger than
24 months of age in Cape Town, 127 courses of post-
exposure IPT were provided, with only two children de-
veloping confirmed TB. Both had fully drug-susceptible
isolates [28]. In a prospective study of prevention in
older HIV-infected children, many with a history of prior
TB infection, both all-cause mortality (16% in the pla-
cebo arm vs. 8% in the IPT arm) and incident cases of
TB (9.9% vs. 3.8%) declined [37]. A subsequent reanaly-
sis assessing the role of IPT and ART in these children
found that the greatest reduction was in children receiv-
ing both ART and IPT [38]. In contrast, a pre-exposure
prevention study enrolling very young infants found high
rates of TB in HIV-infected and HEU infants, but no dif-
ferences between those receiving IPT and placebo [16].
In this study, drug resistance was found to play an im-
portant role in IPT failure [39]. When present, children
typically have primary rather than secondarily acquired
multidrug-resistant (MDR) TB. HIV infection was inde-
pendently associated with prevalent TB disease among
child household contacts of adult MDR-TB cases and
with failure of MDR preventative therapy [40]. In South
African children with MDR-TB, HIV infection was re-
ported in 54, 77, and 22% of cases from Johannesburg,
Kwa-Zulu Natal, and Cape Town, respectively [41–43].
Reviewing the susceptibility/resistance patterns of adult
contacts with TB is an essential component of managing
children with HIV, irrespective of whether or not they
have TB at the time. In children with MDR-TB, HIV is
associated with a poorer outcome [44, 45].
The temporal associations between TB, influenza, and
pneumococcal disease in children suggest a complex
interaction between these infections. There is an in-
crease in TB diagnosis approximately 3 months after the
annual influenza season and a reduction in culture-
confirmed TB in HIV-infected children following receipt
of pneumococcal conjugate vaccines [46, 47]. The Anti-
retroviral Research for Watoto (ARROW) study followed
1,206 HIV-infected children for 5 years after ART and it
included a randomized intervention to stop or continueco-trimoxazole after 96 weeks on ART. In this study, re-
duction in TB was associated not only with the duration
of ART, but also with continued co-trimoxazole pre-
ventative therapy [48].
Diagnosis
Pulmonary TB is the most common disease manifestation
in HIV-infected children, with 85% diagnosed in an early
series of hospitalized South African children [49]. How-
ever, both intra- and extra-thoracic disease may occur
concurrently [49–52]. The principles of TB diagnosis in-
clude the following steps: 1) carefully assess TB contact
history and/or seek proof of infection; 2) enquire about
suggestive symptoms; and 3) seek evidence of active
disease and bacteriologic confirmation. TB symptoms,
though similar in HIV-infected and uninfected infants and
children, overlap with symptoms of other infections and
HIV itself. The chest radiograph may be very difficult to
interpret, especially when there is underlying lung disease.
TB may also be confused with acute pneumonia in
HIV-infected children. It should also be remembered that
HIV-infected children who have not yet been diagnosed
with an underlying HIV infection may present to the
health service with TB [6, 8, 15, 17, 18, 49, 50, 53].
Treatment
The potential drug interactions between the TB therapy
and ART are well known and, in general, TB therapy
should not change. A dual treatment plan should
consider the following questions:
1) What is the suspected or confirmed susceptibility
pattern of M. tuberculosis and which drugs should
be used?
2) Are alternative rifamycins to rifampicin available?
3) Which ART regimen is preferred AND can a
suppressive regimen be given safely?
4) What are the potential drug interactions AND can
adjustments be made if rifampicin is the only
rifamycin available?
In the absence of ART, high mortality in HIV-infected
children with TB was reported [49, 54] and continued
with delayed ART initiation, especially when TB was the
presenting diagnosis. Most deaths occurred within the
first 2 months of delayed ART initiation and were not al-
ways directly TB-related [28].
Pharmacokinetic studies illustrate that both efavirenz
and lopinavir-ritonavir 1:1 in their usual doses provide
appropriate drug levels when co-administered with ri-
fampicin [55, 56]. There are, however, ongoing concerns
over nevirapine dosing and recommendations on dose
adjustments have been suggested [57]. Table 1 summa-
rizes important considerations when treating TB/HIV
Table 1 Summary of the first and second line anti-tuberculosis medications with recommended doses and drug-drug interactions* [60–63]
Drug Dose Recommended Drug-drug interactions with antiretrovirals
Group 1
Isoniazid 7–15 mg/kg once daily None
Rifampicin 10–20 mg/kg once daily Coadministration reduces concentrations ofa NNRTIs,
bPIs, integrase inhibitors
Pyrazinamide 30–40 mg/kg once daily None
Ethambutol 15–25 mg/kg once daily None
Rifabutin 10–20 mg/kg/day (Max Dose 300 mg/day) Boosted PI: increase rifabutin levels and rifabutin dose
reduction is needed
NNRTI: Efavirence reduces the concentration of rifabutin,
increasing the rifabutin dose is recommended in adults
Nevirapine dose adjustment is not needed for rifabutin
Group 2
Kanamycin 15–30 mg/kg once daily, max 1 g
Amikacin 15–22.5 mg/kg once daily, max 1 g
Capreomycin 15–30 mg/kg once daily, max 1 g
Streptomycin 20–40 mg/kg once daily, max 1 g
Group 3
Ofloxacin 15–20 mg/kg once daily, max 800 mg
Levofloxacin (15–20 mg/kg once daily)†, 7.5–10 mg/kg
once daily, max 750 mg
Moxifloxacin 7.5–10 mg/kg once daily, max 400 mg Moxifloxacin concentration could be reduced by ritonavir,
though limited data; buffered didanosine may reduce oral




15–20 mg/kg once daily, max 1 g Possible, unknown
Cycloserine/Terizidone 10–20 mg/kg once or twice daily, max 1 g Unlikely, unknown
Para-aminosalicylic acid
(PAS)
150 mg/kg granules daily in 2–3 divided
doses, max 12 g
Co-administration with efavirenz may reduc PAS AUC
by 50%
Group 5
Linezolid (10 mg/kg twice daily, once daily for
>10 years of age)c
Unlikely




As for bacterial infections Unlikely
Thiacetazone 5–8 mg/kg once daily Contraindicated in HIV-infected individuals
High-dose isoniazid 15–20 mg/kg once daily None
Clarithromycin 7.5–15 mg/kg twice daily Clarithomycin levels increase with boosted atazanavir
and lopinavir with increased risk of toxisity. Clarithomycin
levels are decreased by efavirence, nevirapine and
etravirine Azithromycinn is prefered
Azithromycin 10 mg/kg once daily Prefered macrolide but limited activity and caution required
† Indicates bracketed recommended by some experts, but differs from formal WHO guideline
aNNRTI Non-nucleoside reverse transcriptase inhibitor, bPI Protease inhibitor
cNo formal paediatric dose recommended in WHO guidelines, so presented dose based on experience and expert opinion
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has not been associated with worse outcomes, but des-
pite reassuring data on the pharmacokinetic outcomes
of lopinavir-ritonavir 1:1 concurrent TB therapy may be
a risk factor for failure in children on lopinavir-ritonavirtreatment [62–64]. The World Health Organization
(WHO) also recommends a non-suppressive regimen of
zidovidine, lamivudine and abacavir in children needing
rifampicin as a short-term measure to avoid drug inter-
actions [65]. This is based on the ARROW study. In




are at high risk of
developing TB
High likelihood of household TB exposure
early in life; disproportionate TB/HIV
burden in young mothers
Advanced disease, low CD4 count and
malnutrition are additional risk factors
All children with HIV must be regularly
screened for TB exposure and disease
BCG vaccination is contra-indicated in
children known to be HIV-infected
Strategies to prevent TB High community penetration of adult ART
will reduce TB transmission in communities
Universal early ART initiation in all
HIV-infected
Appropriate use of INH preventative
therapy
Active TB Case finding
Infection prevention and control strategies
History of contact
Early diagnosis of TB Symptoms can overlap with other
opportunistic infections
Pulmonary and extrapulmonary disease
possible
Pulmonary TB can present like acute
pneumonia
A positive TST (≥5 mm) or IGRA confirms
TB infection but not disease
CXR is important; HIV-infected children
more likely to have alveolar opacification
and lung cavities
Collect specimens for culture and Xpert
MTB/RIF® as appropriate
Treating TB/HIV co-infection Use appropriate/standard TB treatment
regimen
Adapt the ART regimen and dosing
Support adherence
Monitor for efficacy and side effects
HIV human immunodeficiency virus, TB tuberculosis, ART antiretroviral
treatment, INH isoniazid, TST tuberculin skin test, IGRA interferon gamma
release assay, CXR chest radiograph
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ase inhibitors (NRTIs) were studied as an intensive
induction and maintenance strategy when combined
with non-nucleoside reverse transcriptase inhibitors
(NNRTIs). Fifty-nine of the 1143 children required a
drug alteration for TB that included stopping or re-
placing the NNRTI nevirapine. In contrast, children tak-
ing efavirenz did not require a drug switch. Triple NRTI
for HIV suppression was effective at 36 weeks, but not
at 144 weeks. The advantage of this latter strategy is
that, although viral suppression is inferior, the risk of
progressive NNRTI and protease inhibitor (PI) ART
resistance was avoided and drug–drug interactions and
logistic complications were minimized [66]. There is no
current guidance on using integrase inhibitors and other
PIs such as darunavir in children, and no data on newer
anti-TB agents such as bedaquiline and delamanid in
HIV-infected children. Nevertheless, ART should be
initiated 2–8 weeks after starting TB therapy so as to re-
duce the risk of IRIS occurring [61]. For example, in TB
meningitis cases deterioration due to paradoxical IRIS
can be devastating and ART should be delayed at least
4 weeks [67, 68]. In Table 2 we highlight key messages
to consider in TB and HIV co-infected children. TB may
be an important challenge and opportunity in achieving
the UNAID 90–90–90 targets [69].
Pneumonia
Pneumonia remains the leading cause of pediatric mortality
and morbidity. Globally, there are approximately 12–14
million hospitalizations and 0.68–0.92 million deaths annu-
ally from pneumonia in children [70–72]. HIV-infected
children are at increased risk of pneumonia that requires
hospital admission and death from this infection. In a
meta-analysis and modelling study, Theodoratou and
colleagues [7] calculated that in 2010 there were 0.6–3.3
million pneumonia episodes and 47,400–153,000 pneumo-
nia deaths in HIV-infected children living in low-resource
settings. Of these cases, 1.3 million (90%) pneumonia epi-
sodes and 93% of the deaths occurred in children younger
than 5 years of age from the Africa region. HIV-infected
children had a 6.5 (95% CI 5.9–7.2) increase in odds of
pneumonia that required hospitalization and they had an
increased risk of death (odds ratio 5.9, 95% CI 2.7–12.7)
[7]. The authors showed that there is also a wide variation
between countries; for example, in Zimbabwe 55% of all
pneumonia deaths are attributed to HIV, compared to 1%
in India [7].
Even with early access to ART, pneumonia remains com-
mon among HIV-infected infants and children. In the
CHER study, pneumonia occurred at a rate of 12.2 infec-
tions/100 person-years in children accessing ART before
12 weeks of age and 26.5 infections/100 person-years in
children accessing ART only after laboratory evidence ofimmune suppression and/or clinical features of HIV infec-
tion became apparent [29]. Poor general health and malnu-
trition, immune depletion, chronic lung disease, increasing
household exposure and vaccine responsiveness may all
contribute to the risk of LRTI. A wide range of pathogens
causing LRTIs and pneumonia in children with HIV is re-
ported [73]. The importance of polymicrobial infection-
s—including combinations of bacterial, viral, P. jirovecii and
mycobacterial infections—is well recognized. Mortality is
increased significantly with increasing numbers of
pathogens. Children with polymicrobial pneumonia have a
10-fold greater risk of dying than children in whom only a
single organism is identified [74].
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HIV-infected children have a higher risk of developing
bacterial pneumonia than uninfected children. This re-
mains a significant problem, even after the introduction of
ART. HIV-infected children with pneumonia are more
likely to have severe disease (including bacteremia), more
complications, higher rates of treatment failure and death,
and possibly more antimicrobial resistance than HIV-
uninfected children [74]. The most common cause of bac-
terial pneumonia remains Streptococcus pneumoniae, but
Staphylococcus aureus is increasingly important. Amongst
Gram-negative bacteria associated with pneumonia in
HIV-infected children, Klebsiella species, Haemophilus
influenzae, Escherichia coli, Pseudomonas aeruginosa and
non-typhoidal Salmonella species are also important [73].
HIV does not affect the radiographic appearance of bac-
terial pneumonia. The two classic patterns of either diffuse
patchy air-space disease of bronchopneumonia, or
confluent air-space disease with air bronchograms of lobar
or segmental pneumonia can be found [75]. Necrotizing
pneumonia, a severe complication of community-acquired
pneumonia in non-HIV infected children, is characterized
by liquefaction and cavitation of lung tissue and is being
seen increasingly [76, 77]. The most common cause is S.
pneumoniae, and although in the authors’ experience it also
occurs in HIV-infected children, this has not been reported
to date in the literature. The chest radiographs in necrotiz-
ing pneumonia frequently demonstrate both pleural and
parenchymal involvement. The so-called ‘atypical pneumo-
nias’ can present with a variable radiographic appearance,
which includes reticulonodular infiltration, patchy or
confluent air-space disease or a combination of all three
patterns [78]. It is, therefore, very important to correlate
the radiographic appearance with the clinical setting [78].
Without appropriate vaccination or ART, HIV-infected
children experience a 40-fold increase in the risk of
pneumococcal bacteremia, pneumonia and meningitis
compared to vaccinated HIV-uninfected children, and they
also often experience multiple episodes of invasive disease
[79]. In South Africa, ART decreased the pneumonia
burden by half with an even higher (65.2%) decline in mor-
tality from invasive pneumococcal disease [80]. Vaccinating
with the pneumococcal conjugate vaccine causes a signifi-
cant reduction in vaccine-type serotype colonization and
disease [79–81]. The reported increases in empyema with
non-vaccine serotypes are mostly from areas with very low
incidence of HIV and the real incidence of empyema in
HIV-positive children is not known [82].
Viral pneumonia
Viral infections play a major role in LRTIs and viruses
are commonly identified in HIV-infected children hospi-
talized with these infections. Viral LRTIs may also play
an important role in the pathogenesis of bacterialpneumonia and in the epidemiology of TB. In a large
study from South Africa at least one virus was identified
in 68% of HIV-infected children younger than 5 years of
age and in 58% of those aged 5–14 years presenting with
symptoms of a LRTI. More than one respiratory virus
was found in 28 and 19% of children within these age
groups, respectively. In children younger than 5 years
the most common viruses detected were human rhino-
virus (36%), adenovirus (32%), respiratory syncytial virus
(RSV) (13%), enterovirus (8%), parainfluenza (9%) and
influenza viruses (7%) [83, 84]. In addition, human boca-
virus, human polyomaviruses and human coronaviruses
are increasingly found in children with LRTIs, including
those with HIV [85]; however, it is difficult to attribute
causality to these viruses [85].
RSV is a very important pathogen in infants and young
children and a common cause of LRTIs that require
healthcare visits and hospitalization. HIV is an import-
ant risk factor for severe RSV infections, especially in
high-burden settings [86]. HIV-infected children are
older and may develop RSV outside of the seasonal
peaks. Compared with HEU children, there is an in-
creased incidence of hospitalization (3–5-fold) in chil-
dren with HIV, and they tend to stay in hospital longer
and have a higher risk of death. In a South African study
of RSV-associated LRTI infection, 49 of the 1157 chil-
dren with confirmed RSV were HIV-infected. In this
study, ART data was only available for 12 cases, 6 of
whom received ART. Four of the 9 deaths in this study
occurred in HIV-infected children; however, their ART
data are unknown [87].
Influenza is an important cause of pneumonia
hospitalization and death. ART naïve HIV-infected chil-
dren are up to 8 times more likely to be hospitalized and
have a higher case fatality rate (8% in HIV-infected vs.
2% in uninfected children) [88, 89]. In a prospective
South African study, pandemic and seasonal H1N1 in-
fluenza had a similar clinical course in HIV-infected
children [90]. Giannattasio et al. reported on 11 HIV-
infected and 30 otherwise healthy children hospitalized
for H1N1 influenza. Leukopenia was recorded in 64% of
HIV-infected and in 20% of healthy children (p = 0.01).
Interstitial pneumonia was more frequent in HIV-
positive children and consolidation was more frequent
in HIV-negative children. Overall, 91% of HIV-positive
children received oseltamivir. The H1N1 influenza at-
tack rate was very high (20%) in HIV-infected children,
but it consistently ran a mild course [91]. Annual vaccin-
ation with the seasonal influenza vaccine is recom-
mended, but efficacy may be influenced by decreased
vaccine immunogenicity reported in some studies [92].
CMV is a common co-infection in HIV-infected chil-
dren and is frequently isolated from urine and respira-
tory secretions [93, 94]. Congenital and post-partum
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fected infants and CMV infection may be associated
with breastfeeding acquisition of HIV [95, 96]. The role
of co-infection with CMV in children, especially those
suspected of having P. jiroveci pneumonia (PJP), is
poorly understood, but CMV itself can cause fatal
pneumonia [94, 97]. Postmortem studies from Africa re-
ported that in the 0–5 months age group, CMV (42.1%)
was the second most common cause of fatal pneumonia
after P. jirovecci (51.3%) [9]. The isolation of CMV by
culture or polymerase chain reaction (PCR) from various
sites or specimens does not prove that the child has
CMV pneumonia. The chest radiographic appearance of
PJP and CMV pneumonia can be very similar (diffuse al-
veolar disease). In children being ventilated for PJP and
not responding to treatment for PJP, CMV was histologi-
cally proven in 72% of cases and associated with a poor
outcome [97, 98]. CMV viremia is common in all infants
with pneumonia, and a viral logarithmic load (to the
base 10) of 4.6 or more was predictive of pneumonia in
a study of from Cape Town [99]. In HIV-infected infants
with severe pneumonia from suspected PJP, we would
suggest that empiric treatment for CMV infection with
either ganciclovir or valgancyclovir be used wherever
possible, until such time that CMV infection can be
excluded.
Despite access to effective vaccination, measles re-
mains an important pathogen in children [100]. In set-
tings with a high HIV burden, a significant number of
children hospitalized with measles are also infected with
HIV—such as Zambia, where up to 17% of hospitalized
children with measles had HIV infection [101]. HIV-
infected children with measles are significantly younger
than uninfected children and often have not yet received
the first vaccination of their primary measles containing
vaccine schedule, even if that is scheduled at 9 months
of age [102, 103]. Consequently, the WHO recommends
first dose of a measles containing vaccine be adminis-
tered at the age of 6 months in HIV-infected children
[104]. Measles is generally thought to be more severe in
HIV-infected children—both the duration of illness prior
to hospitalization and the duration of hospitalization is
longer [102, 103]. In low-resource settings, the case
fatality rate is 2–7-fold higher in children with HIV
[103, 104]. The effect of ART in preventing measles or
modifying its severity is not fully understood, but initi-
ation of ART at the time of admission for measles did
not prevent readmission during a recent large measles
outbreak in Cape Town [102].
Pneumocystis jiroveci pneumonia
P. jirovecii is a common and important pathogen in HIV-
infected children and causes a severe, rapidly progressive
pneumonia with a high mortality rate despite access toantibiotic therapy [93, 94]. This pathogen is also increas-
ingly reported in severe pneumonia in young HEU infants
[105, 106]. The chest radiograph findings show increased
lung volumes (78%) and diffuse parenchymal opacification
(64%) that lead ultimately to diffuse alveolar opacification
(92%). This usually happens within 72 h of presentation
[107]. Clinically, lack of fever, high respiratory rate, low
oxygen saturation and absence of co-trimoxazole pre-
ventative therapy is suggestive of PJP. Real-time PCR is
better than immunofluorescence at making a microbio-
logic diagnosis [108]. When PJP is suspected, high-dose
co-trimoxazole and steroids should be added to the man-
agement of severe LRTI.
The most important strategy to prevent PJP is by using
co-trimoxazole prophylactic therapy from 6 weeks of age
[109]. Stopping co-trimoxazole after CD4 recovery was
studied in African children, and its continuation may
have additional benefits beyond PJP prophylaxis, includ-
ing TB prevention [48].
Conclusions
Acute respiratory compromise caused by M. tuberculosis
and other lung pathogens is a major cause of disease
and death in HIV-infected children. Furthermore, many
also develop chronic lung disease with bronchiectasis
due to recurrent lung infections [110, 111]. In children
with delayed ART initiation, nearly a third (28%) develop
chronic lung disease with significantly compromised
lung function [112]. This highlights the need for early
ART initiation and universal ART access for all HIV-
infected children to reduce the high burden of lung dis-
ease. Finally, vaccination, appropriate use of preventive
therapy and early effective treatment of lung infections,
including TB, are also essential to ensure optimal lung
health in HIV-infected children.
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